Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia

References (18)

1. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39–60. PubMed CrossRef
2. Wagner E, Siafis S, Fernando P, et al. Efficacy and safety of clozapine in psychotic disorders – a systematic quantitative meta-review. Transl Psychiatry. 2021;11(1):487. PubMed
3. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. PubMed CrossRef
4. Iqbal E, Govind R, Romero A, et al. The side effect profile of clozapine in real world data of three large mental health hospitals. PLoS One. 2020;15(12):e0243437. PubMed CrossRef
5. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477–2482. PubMed CrossRef
6. Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase^®. Psychol Med. 2021;51(9):1459–1466. PubMed
7. Tiihonen J, Tanskanen A, Bell JS, et al. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry. 2022;9(5):353–362. PubMed CrossRef
8. Dawson JL, Sluggett JK, Procter NG, et al. Hematological and other cancers in people using clozapine: analysis of Australian spontaneous reports between 1995 and 2020. J Clin Psychopharmacol. 2023;43(4):333–338. PubMed CrossRef
9. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. Accessed April 27, 2023. https://www.whocc.no/atcddd/indexdatabase
10. Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. PubMed CrossRef
11. Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
12. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull. 2019;45(2):315–329. PubMed CrossRef
13. Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. PubMed CrossRef
14. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. PubMed CrossRef
15. US Department of Veterans Affairs. Veterans’ diseases associated with Agent Orange. Accessed March 19, 2023. https://www.publichealth.va.gov/exposures/agentorange/conditions/index.asp
16. Nooka AK, Lonial S, Boise LH, et al. Risk factors for development of myeloma: role of smoking and alcohol. Blood. 2014;124(21):2604.
17. de Leon J, De Las Cuevas C, Sanz EJ, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):537–538. PubMed
18. Schulte PF, Cohen D, Veerman SR, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):538–539. PubMed CrossRef